Alzamend Neuro, Inc. (ALZN)
Largest Insider Buys in Sector
ALZN Stock Price History Chart
ALZN Stock Performance
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, …
Insider Activity of Alzamend Neuro, Inc.
Over the last 12 months, insiders at Alzamend Neuro, Inc. have bought $9,146 and sold $0 worth of Alzamend Neuro, Inc. stock.
On average, over the past 5 years, insiders at Alzamend Neuro, Inc. have bought $4.74M and sold $63,434 worth of stock each year.
Highest buying activity among insiders over the last 12 months: AULT MILTON C III (10 percent owner) — $9,146.
The last purchase of 75 shares for transaction amount of $206 was made by AULT MILTON C III () on 2024‑08‑06.
List of Insider Buy and Sell Transactions, Alzamend Neuro, Inc.
| 2024-08-06 | 75 0.0107% | $2.75 | $206 | -26.20% | ||||
| 2024-07-31 | 25 0.0034% | $3.74 | $93 | -5.94% | ||||
| 2024-04-19 | 1,000 0.0148% | $0.69 | $688 | -43.49% | ||||
| 2024-04-01 | 334 0.005% | $0.91 | $304 | -55.00% | ||||
| 2024-01-05 | 2,000 0.0308% | $1.06 | $2,127 | -38.95% | ||||
| 2024-01-05 | 5,000 0.0737% | $1.02 | $5,093 | -38.95% | ||||
| 2023-12-26 | 10 percent owner | 500 0.007% | $0.90 | $450 | -35.57% | |||
| 2023-12-22 | 10 percent owner | 200 0.0029% | $0.92 | $185 | -35.59% | |||
| 2023-09-26 | Chief Financial Officer | 53,000 0.0564% | $0.19 | $10,234 | -69.15% | |||
| 2023-05-24 | 10 percent owner | 18,000 0.0185% | $0.59 | $10,705 | -86.52% | |||
| 2023-04-28 | Chief Executive Officer | 37,000 0.0372% | $0.54 | $19,999 | -67.50% | |||
| 2023-03-22 | director | 10,000 0.0101% | $0.43 | $4,350 | -47.91% | |||
| 2023-03-17 | 10 percent owner | 5,000 0.0055% | $0.43 | $2,149 | -42.00% | |||
| 2023-03-16 | 10 percent owner | 4,000 0.0045% | $0.50 | $2,006 | -48.96% | |||
| 2023-02-15 | 10 percent owner | 1,000 0.001% | $0.60 | $597 | -50.44% | |||
| 2022-12-28 | director | 3,100 0.0033% | $0.56 | $1,745 | -8.49% | |||
| 2022-12-27 | director | 900 0.0009% | $0.59 | $532 | -18.01% | |||
| 2022-12-21 | director | 5,000 0.0054% | $0.81 | $4,050 | -35.56% | |||
| 2022-12-19 | director | 23,000 0.023% | $0.82 | $18,813 | -40.35% | |||
| 2022-12-16 | director | 20,000 0.0218% | $0.90 | $17,960 | -40.63% |
Insider Historical Profitability
| AULT MILTON C III | 77268 1.7265% | $1.36 | 105 | 4 | <0.0001% | |
| Katzoff David J | Chief Financial Officer | 81000 1.8099% | $1.36 | 1 | 0 | <0.0001% |
| Jackman Stephan | Chief Executive Officer | 45500 1.0167% | $1.36 | 1 | 0 | |
| McGrath Lynne Fahey | director | 10000 0.2234% | $1.36 | 1 | 1 |